Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.

Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Chairman.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Randomized, double-blind, multicenter, controlled trial.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery Nancy A. Nussmeier, M.D., Andrew A. Whelton, M.D., Mark T. Brown,

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Baseline Prevalence of Metabolic Syndrome and Individual Components Among 4258 Older Adults Dariush Mozaffarian, et al. Arch Intern Med. 2008;168:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

The SPRINT Research Group

Baseline Mean Daily Servings of Coffee and Other Beverages and of Caffeine in Women in the Iowa Women’s Health Study, 1986* *Data are given as.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn

Section 3: CKD, CVD and mortality

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Fig 3. Time trends for infant mortality rate and hazard ratio according to the deprivation quintiles. (A) Time trend for the infant mortality rate according.

TNT: Baseline and final LDL cholesterol levels

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

Baseline characteristics of patients

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

Rounded incidence values (%) of renal and nonrenal events

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Relative risk of major events with atenolol vs placebo

Health ABC: Mortality risk by quintile of cystatin C

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

Fung TT, et al. Circulation 2009;119:

Risk of major congenital malformations among study infants according to fetal exposure to antihypertensives during first trimester alone* Variable ACE.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p for noninferiority < 0.001)

Cystatin C levels and risk of death from all causes

Risk for BMI outcome (%)

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Enrollment and Outcomes

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics by Tertiles of Homocysteine

Baseline Characteristics of the Subjects

Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.

Characteristics of the Patients at Baseline*

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Women’s Health Study: Baseline Characteristics Part 1

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Characteristics of Participants in the Nurses Health Study According to Alcohol Intake Meir J.Stampfer et al N Engl J Med 2005;352:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of the Patients – Part I

Baseline plasma levels of cathepsin D (A), cathepsin L (B) and cystatin B (C) are increased in individuals who developed coronary events (CEs) during follow-up.

Baseline Characteristics of the Patients - Part I

Representative Light Micrographs of Kidney Sections Illustrating the Histologic Scoring Criteria Giuseppe Remuzzi, et al, N Engl J Med 2006;3354:

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Risk of cardiovascular disease mortality by cardiorespiratory fitness and body mass index categories, 2316 men with type 2 diabetes at baseline, 179 deaths.

Presentation transcript:

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl J Med 2005;352:2049-60

Mortality from All Causes According to Quintile of Measuresof Renal Function Michael G.Shlipak et al N Engl J Med 2005;352:2049-60

Mortality from All Causes According to Quintile of Both Cystatin C and Creatinine Michael G.Shlipak et al N Engl J Med 2005;352:2049-60

Risk of Adverse Outcomes According to Measures of Renal Function among Elderly Participants in the Cardiovascular Health Study - Part 1 Michael G.Shlipak et al N Engl J Med 2005;352:2049-60

Risk of Adverse Outcomes According to Measures of Renal Function among Elderly Participants in the Cardiovascular Health Study - Part 2 Michael G.Shlipak et al N Engl J Med 2005;352:2049-60

Risk of Adverse Outcomes According to Measures of Renal Function among Elderly Participants in the Cardiovascular Health Study - Part 3 Michael G.Shlipak et al N Engl J Med 2005;352:2049-60

Risk of Death and Cardiovascular Events According to Cystatin C Risk Categories among Elderly Participants in the Cardiovascular Health Study Michael G.Shlipak et al N Engl J Med 2005;352:2049-60